UMIN-CTR Clinical Trial
| Unique ID issued by UMIN | UMIN000004381 |
|---|---|
| Receipt number | R000005236 |
| Scientific Title | fMRI study on effect of NK1 antagonist (Aprepitant) on cognitive function in normal subjects |
| Date of disclosure of the study information | 2010/10/14 |
| Last modified on | 2019/07/26 10:59:49 |
* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments
Basic information
Public title
fMRI study on effect of NK1 antagonist (Aprepitant) on cognitive function in normal subjects
Acronym
fMRI study on effect of NK1 antagonist (Aprepitant) on cognitive function in normal subjects
Scientific Title
fMRI study on effect of NK1 antagonist (Aprepitant) on cognitive function in normal subjects
Scientific Title:Acronym
fMRI study on effect of NK1 antagonist (Aprepitant) on cognitive function in normal subjects
Region
| Japan |
Condition
Condition
Substance-related disorders, Mood disorders, Anxiety disorders
Classification by specialty
| Psychiatry |
Classification by malignancy
Others
Genomic information
NO
Objectives
Narrative objectives1
The aim of this study is to investigate the effect of NK1 antagonist (Aprepitant) on human cognitive function.
Basic objectives2
Efficacy
Basic objectives -Others
Trial characteristics_1
Confirmatory
Trial characteristics_2
Explanatory
Developmental phase
Not applicable
Assessment
Primary outcomes
Comparison between placebo and Aprepitant conditions.
Key secondary outcomes
Base
Study type
Interventional
Study design
Basic design
Cross-over
Randomization
Randomized
Randomization unit
Individual
Blinding
Single blind -participants are blinded
Control
Placebo
Stratification
Dynamic allocation
Institution consideration
Blocking
Concealment
Intervention
No. of arms
2
Purpose of intervention
Treatment
Type of intervention
| Medicine |
Interventions/Control_1
1day 1 time Aprepitant 125mg
washout duration 1 week
1day 1 time placebo (lactose)
Interventions/Control_2
1day 1 time placebo (lactose)
washout duration 1 week
1day 1 time Aprepitant 125mg
Interventions/Control_3
Interventions/Control_4
Interventions/Control_5
Interventions/Control_6
Interventions/Control_7
Interventions/Control_8
Interventions/Control_9
Interventions/Control_10
Eligibility
Age-lower limit
| 20 | years-old | <= |
Age-upper limit
| 40 | years-old | > |
Gender
Male and Female
Key inclusion criteria
healthy adult
Key exclusion criteria
patients with psychiatric disorder
patients with hepatic, kidney, cardiac disorders
patients taking other drugs
Target sample size
20
Research contact person
Name of lead principal investigator
| 1st name | Hidenori |
| Middle name | |
| Last name | Suzuki |
Organization
Nippon Medical School
Division name
Pharmacology
Zip code
113-8602
Address
1-1-5, Sendagi, Bunkyo-ku, Tokyo 113-8602, Japan
TEL
03-3822-2131
hsuzuki@nms.ac.jp
Public contact
Name of contact person
| 1st name | Yumiko |
| Middle name | |
| Last name | Ikeda |
Organization
Nippon Medical School
Division name
Pharmacology
Zip code
113-8602
Address
1-1-5, Sendagi, Bunkyo-ku, Tokyo 113-8602, Japan
TEL
03-3822-2131
Homepage URL
y-ikeda@nms.ac.jp
Sponsor or person
Institute
Nippon Medical School
Institute
Department
Personal name
Funding Source
Organization
MEXT
Organization
Division
Category of Funding Organization
Japanese Governmental office
Nationality of Funding Organization
Japan
Other related organizations
Co-sponsor
Name of secondary funder(s)
IRB Contact (For public release)
Organization
Clinical Research Promotion Department, Nippon Medical School
Address
1-1-5, Sendagi, Bunkyo-ku, Tokyo 113-8602, Japan
Tel
03-3822-2131
clinicaltrial@nms.ac.jp
Secondary IDs
Secondary IDs
NO
Study ID_1
Org. issuing International ID_1
Study ID_2
Org. issuing International ID_2
IND to MHLW
Institutions
Institutions
Other administrative information
Date of disclosure of the study information
| 2010 | Year | 10 | Month | 14 | Day |
Related information
URL releasing protocol
Publication of results
Unpublished
Result
URL related to results and publications
Number of participants that the trial has enrolled
Results
Results date posted
Results Delayed
Results Delay Reason
Date of the first journal publication of results
Baseline Characteristics
Participant flow
Adverse events
Outcome measures
Plan to share IPD
IPD sharing Plan description
Progress
Recruitment status
Completed
Date of protocol fixation
| 2010 | Year | 06 | Month | 18 | Day |
Date of IRB
| 2010 | Year | 06 | Month | 18 | Day |
Anticipated trial start date
| 2010 | Year | 10 | Month | 01 | Day |
Last follow-up date
| 2011 | Year | 07 | Month | 31 | Day |
Date of closure to data entry
Date trial data considered complete
Date analysis concluded
Other
Other related information
Management information
Registered date
| 2010 | Year | 10 | Month | 13 | Day |
Last modified on
| 2019 | Year | 07 | Month | 26 | Day |
Link to view the page
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000005236
